Work Area: Transactions

Latest content

Pfizer and Amgen fight to avoid patent cliff falls in multi-billion dollar buying sprees

With significant revenue drop-offs from existing branded products set to decline steeply in the second half of this decade, major portfolio acquisitions are a priority for both companies

10 August 2022

IPBC Asia all set for Tokyo this autumn

The Asia-Pacific region’s premier event about the business of IP will take place in the Japanese capital from 31 October to 2 November

10 August 2022

Intel transfers 5,000 assets to IPValue in major patent deal

The portfolio covers a wide range of the tech produced by the Silicon Valley giant and will now be monetised by an entity named Tahoe Research Limited

08 August 2022

The contribution patents make to enterprise value

No commonly used valuation methods are much help at putting a number on an entire portfolio unless there is a specific transaction on the horizon. Cipher’s Nigel Swycher and Steve Harris suggest an original methodology to fill this gap

03 August 2022

Sanofi farms out more IP as part of “play to win” strategy

The French company is one of several big pharmas to have offloaded deprioritised drugs in recent months

29 July 2022

Be proactive about IP ownership

Employees are not necessarily always renumerated for their patented or patentable inventions. Therefore, employers are advised to take a number of steps to avoid disruptive issues over the ownership of intellectual property created by their employees.

27 July 2022

UK government blocks IP deal with Chinese company using radical new powers

Recently implemented legislation gives the British government the ability to intervene in IP transactions

22 July 2022

Patent ownership when your R&D staff depart

IP transactions face difficulties when inventor employees leave a company, raising questions as to whether their inventions are owned by the company. Often, the type of employee and the jurisdiction in question are key factors.

20 July 2022

Royalty Pharma spends $1.3 billion in latest drug revenue rights purchase

Royalty transactions are an increasingly attractive means of cashing in on life sciences innovation, and the returns can be significant

15 July 2022

Pfizer to commercialise its IP with the help of trailblazing Roivant approach

The partnership is aimed at helping the pharma giant to moentise deprioritised IP in the autoimmune space

04 July 2022

Get unlimited access to all IAM content